Technical analysis of Rallybio Corporation (RLYB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Price Performance
| 1 month | +1.91% |
| 3 months | +7.01% |
| Year-to-date | +211.29% |
| 1 year | +275.60% |
| 3 years | -55.03% |
| 5 years | -83.30% |
52-Week Range
| 52-week High | $17.57 |
| 52-week Low | $3.67 |
| Avg Volume (90d) | 44K |
Technical Indicators
| SMA 50 | $16.51 |
| SMA 200 | $11.17 |
| Beta | -1.20 |
| 30-day Volatility (annualised) | 23.3% |
| Price vs SMA 50 | +3.5% |
| Price vs SMA 200 | +53.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.58 | |
| 2025-11 | $5.21 | -6.6% |
| 2025-12 | $5.49 | +5.4% |
| 2026-01 | $5.14 | -6.4% |
| 2026-02 | $7.54 | +46.7% |
| 2026-03 | $8.97 | +19.0% |
| 2026-04 | $8.98 | +0.1% |
| 2026-05 | $14.46 | +61.0% |
| 2026-06 | $16.00 | +10.7% |
| 2026-07 | $15.93 | -0.4% |
| 2026-08 | $16.79 | +5.4% |
| 2026-09 | $17.09 | +1.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $17.09 |
| Market Cap | $91M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.14 |
| Price / Book | 1.02 |
| EV / EBITDA | -0.11 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 27.26 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.86 |